Presentations on 2018 Hot Topics in Hematologic Malignancies - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations on 2018 Hot Topics in Hematologic Malignancies

A Close Look at DLBCL, AML, and CLL

Not a member of My prIME? Join now for instant access.

Stay current on hot topics in hematologic malignancies with downloadable slides from our live satellite symposium at EHA. The advent of targeted therapies and immunotherapy has led to a vast change in the treatment possibilities for acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL). These downloadable slides focus on the newest approved agents in these hematologic malignancies and provide the latest clinical trial updates on novel agents.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Jun 18, 2018

Expiration Date

Jun 18, 2019

Featured Expert

  • Christian Gisselbrecht, MD, PhD, Hôpital Saint-Louis, Paris, France

Featured Topic

Current state-of-the-art therapy for DLBCL in 2018

Featured Expert

  • Christian Gisselbrecht, MD, PhD, Hôpital Saint-Louis, Paris, France

Featured Topic

New targeted therapies on the horizon for DLBCL

Featured Expert

  • Hagop M. Kantarjian, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Current state-of-the-art therapy for AML in 2018

Featured Expert

  • Hagop M. Kantarjian, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

New targeted therapies on the horizon for AML

Featured Expert

  • Anders Österborg, MD, PhD, Karolinska University Hospital, Stockholm, Sweden

Featured Topic

Current state-of-the-art therapy for CLL in 2018

Featured Expert

  • Anders Österborg, MD, PhD, Karolinska University Hospital, Stockholm, Sweden

Featured Topic

New targeted therapies on the horizon for CLL

This educational activity has been designed for hematologists, hematologist/oncologists, and other healthcare providers who treat patients with hematologic malignancies.

After successful completion of this educational activity, participants should be able to:

  • Describe the mechanisms of action of novel targeted and immunologic therapies for AML, DLBCL, and CLL
  • Identify ongoing clinical studies investigating emerging targeted and immunologic therapies for AML, DLBCL, and CLL

This educational activity is supported by grants from Helsinn Healthcare SA; Karyopharm Therapeutics; and TG Therapeutics, Inc.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Gisselbrecht has disclosed that he has received grants or research support from Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kantarjian has disclosed that he has received grants or research support from Amgen, Ariad, Astex, BMS, Novartis, and Pfizer. He has also received honoraria or consultation fees from AbbVie, Amgen, ARIAD, BMS, Immunogen, Orsinex, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Österborg has disclosed that he has received grants or research support from AbbVie, Gilead, and Janssen. He has also received honoraria or consultation fees from Gilead. He disclosed shareholder stock in Kancera. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.